- Home
- AIRE vs CLYM Comparison
AIRE vs CLYM Comparison
Compare AIRE & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRE
- CLYM
- Stock Information
- Founded
- AIRE 2021
- CLYM 2018
- Country
- AIRE United States
- CLYM United States
- Employees
- AIRE N/A
- CLYM N/A
- Industry
- AIRE
- CLYM
- Sector
- AIRE
- CLYM
- Exchange
- AIRE Nasdaq
- CLYM NYSE
- Market Cap
- AIRE 86.1M
- CLYM 101.6M
- IPO Year
- AIRE N/A
- CLYM 2021
- Fundamental
- Price
- AIRE $0.65
- CLYM $1.27
- Analyst Decision
- AIRE Strong Buy
- CLYM
- Analyst Count
- AIRE 1
- CLYM 0
- Target Price
- AIRE $3.00
- CLYM N/A
- AVG Volume (30 Days)
- AIRE 252.6K
- CLYM 154.3K
- Earning Date
- AIRE 05-23-2025
- CLYM 05-14-2025
- Dividend Yield
- AIRE N/A
- CLYM N/A
- EPS Growth
- AIRE N/A
- CLYM N/A
- EPS
- AIRE N/A
- CLYM N/A
- Revenue
- AIRE $948,420.00
- CLYM N/A
- Revenue This Year
- AIRE $206.83
- CLYM N/A
- Revenue Next Year
- AIRE $158.08
- CLYM N/A
- P/E Ratio
- AIRE N/A
- CLYM N/A
- Revenue Growth
- AIRE 419.58
- CLYM N/A
- 52 Week Low
- AIRE $0.52
- CLYM $1.05
- 52 Week High
- AIRE $4.49
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- AIRE 33.13
- CLYM N/A
- Support Level
- AIRE $0.60
- CLYM N/A
- Resistance Level
- AIRE $0.85
- CLYM N/A
- Average True Range (ATR)
- AIRE 0.07
- CLYM 0.00
- MACD
- AIRE 0.02
- CLYM 0.00
- Stochastic Oscillator
- AIRE 40.27
- CLYM 0.00
About AIRE reAlpha Tech Corp.
ReAlpha Tech Corp is a real estate technology company that develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability; and has an app for investment into the properties that it purchased aimed at retail investors. The company's reportable segments are; Platform Services, which derives key revenue, and the Rental business segment.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.